Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;3(4):157-63.
doi: 10.1007/BF03160932.

Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005

Mathias B Forrester  1
Affiliations

Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005

Mathias B Forrester. J Med Toxicol. 2007 Dec.

Abstract

Introduction: Little data exist on potentially adverse valsartan ingestions reported to poison control centers.

Methods: Using adult ingestions of valsartan reported to Texas poison control centers during 2000-2005, I determined the proportion of cases involving serious outcomes for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI).

Results: Thirteen (7%) of 185 total cases involved serious outcomes. Serious outcomes were significantly more likely to occur with a maximum dose 320 mg (RR 9.06, CI 1.30-100.14) or 4 tablets (RR 9.00, CI 2.07-39.11) or where the circumstances of the exposures involved self-harm or malicious intent (RR 17.28, CI 4.98-67.13).

Conclusions: The severity of the medical outcome associated with adult valsartan ingestions depended on the dose and the circumstances of the ingestion. Such information is useful for creating triage guidelines for the management of adult valsartan ingestions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm. 2000;57:1231–1241. - PubMed
    1. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(1):S73–S86. doi: 10.1038/sj.jhh.1000991. - DOI - PubMed
    1. McInnes GT. Clinical advantage of valsartan. Cardiology. 1999;91(1):14–18. doi: 10.1159/000047283. - DOI - PMC - PubMed
    1. Leiken JB, Paloucek FP, editors. Poison and Toxicology Compendium with Symptoms Index. Hudson, Ohio: Lexi-Corp Inc; 1998. pp. 556–556.
    1. Novartis. Diovan® valsartan tablets. [updated 2006 Apr;cited2006 Oct 31]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf

Publication types

MeSH terms

LinkOut - more resources